Transplant patients at risk of Drug-Resistant virus under microscope
NCT ID NCT05234723
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is looking at 100 adult patients who have had an organ or stem cell transplant and later developed a CMV infection that is resistant or hard to treat with standard antiviral drugs. Researchers want to find out how common this problem is and what factors make it more likely. The goal is to use this information to design better ways to prevent and manage these tough infections in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors identify which transplant patients are at highest risk for drug-resistant CMV, leading to better prevention and treatment strategies.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly test any new drug or therapy, and results may not lead to immediate changes in patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AOU Città della salute e della scienza
RECRUITINGTorino, 10126, Italy
-
ASST dei Sette Laghi
NOT_YET_RECRUITINGVarese, 21100, Italy
-
Azienda Ospedale-Università Padova
NOT_YET_RECRUITINGPadova, 35128, Italy
-
Azienda Ospedaliera dei Colli
NOT_YET_RECRUITINGNaples, 80131, Italy
-
Azienda Ospedaliero-Universitaria di Modena
RECRUITINGModena, 41125, Italy
-
Centre Hospitalier Universitaire de Limoges
NOT_YET_RECRUITINGLimoges, Limoges, 87000, France
-
Centre hospitalier universitaire vaudois (CHUV)
NOT_YET_RECRUITINGLausanne, Lausanne, 1011, Switzerland
-
Gregorio Marañón General University Hospital
NOT_YET_RECRUITINGMadrid, 28007, Spain
-
Helsinki University Central Hospital
NOT_YET_RECRUITINGHelsinki, Helsinki, 00290, Finland
-
Hospital Clinic
RECRUITINGBarcelona, 08036, Spain
-
Humanitas Research Hospital
NOT_YET_RECRUITINGRozzano, Milano, 20089, Italy
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
RECRUITINGBologna, Bologna, 40138, Italy
-
Institut Jules Bordet
NOT_YET_RECRUITINGBrussels, 1070, Belgium
-
Instituto Maimónides de Investigación Biomédica de Córdoba
RECRUITINGCórdoba, 14004, Spain
-
Istituto mediterraneo per i trapianti e terapie ad alta specializzazione (ISMETT)
RECRUITINGPalermo, Palermo, 90127, Italy
-
MD Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030-4009, United States
-
Manchester University NHS Foundation Trust
NOT_YET_RECRUITINGManchester, United Kingdom
-
Ospedale San Martino
NOT_YET_RECRUITINGGenova, 16132, Italy
-
Policlinico di Milano
RECRUITINGMilan, 20122, Italy
-
São João University Hospital
NOT_YET_RECRUITINGPorto, 4200-319, Portugal
-
University Hospital 12 de Octubre
NOT_YET_RECRUITINGMadrid, 28026, Spain
-
University Hospital Zurich
NOT_YET_RECRUITINGZurich, 8091, Switzerland
-
University Hospitals Leuven
NOT_YET_RECRUITINGLeuven, 3000, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells predict herpesvirus danger in transplant patients?
- Can specially grown immune cells from donors beat viruses that won't go away?
- Immune cell levels may predict who will develop severe CMV after transplant
- Lab-Grown immune cells take aim at Life-Threatening viruses in vulnerable patients
- Hidden immune fire: could CMV or autoimmunity be fueling HIV-Related inflammation?
- Newborn blood spots may reveal hidden risks from common virus